EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC 3.0

The Efficacy and Safety of Crisugabalin (HSK16149) in Fibromyalgia Patients: Protocol for a Prospective Randomized Open Blinded-Endpoint (PROBE) Study

Minying Liu, Renshu Li, Huacheng Zhou, Zhaohui Xie, Yunwu He, Fei Ren, Xiaobo Feng, Bifa Fan, Shuiqing Li iD, Fang Luo iD, Daying Zhang

Journal of Pain Research · 2026-03 · Volume 19 · 1-10

DOI: 10.2147/jpr.s580694 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Journal of Pain Research, 2026-03. Verfasst von Minying Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

blinded-endpointcrisugabalinfibromyalgiapregabalinrandomized controlled trial

Autor:innen und Institutionen

  • Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
  • Department of Pain Management, Yanbian University Hospital, Yanji, People's Republic of China.
  • Department of Pain Management, Fourth Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
  • Department of Pain Management, First Hospital of Lanzhou University, Lanzhou, People's Republic of China.
  • Department of Pain Management, Second Hospital Affiliated to University of South China, Hengyang, People's Republic of China.
  • Department of Pain Management, Xiangya Hospital of Central South University, Changsha, People's Republic of China.

ORCID-Profile: Shuiqing Li, Fang Luo

Zitieren

APA

Liu, M., Li, R., Zhou, H., Xie, Z., He, Y., Ren, F., Feng, X., Fan, B., Li, S., Luo, F., & Zhang, D. (2026). The Efficacy and Safety of Crisugabalin (HSK16149) in Fibromyalgia Patients: Protocol for a Prospective Randomized Open Blinded-Endpoint (PROBE) Study. Journal of Pain Research, Volume 19, 1-10. https://doi.org/10.2147/jpr.s580694

Vancouver

Liu M, Li R, Zhou H, Xie Z, He Y, Ren F, et al. The Efficacy and Safety of Crisugabalin (HSK16149) in Fibromyalgia Patients: Protocol for a Prospective Randomized Open Blinded-Endpoint (PROBE) Study. Journal of Pain Research. 2026;Volume 19:1-10. doi:10.2147/jpr.s580694

BibTeX
@article{Liu2026,
  author = {Liu, Minying and Li, Renshu and Zhou, Huacheng and Xie, Zhaohui and He, Yunwu and Ren, Fei and Feng, Xiaobo and Fan, Bifa and Li, Shuiqing and Luo, Fang and Zhang, Daying},
  title = {The Efficacy and Safety of Crisugabalin (HSK16149) in Fibromyalgia Patients: Protocol for a Prospective Randomized Open Blinded-Endpoint (PROBE) Study},
  journal = {Journal of Pain Research},
  year = {2026},
  volume = {Volume 19},
  pages = {1--10},
  doi = {10.2147/jpr.s580694}
}
Kostenlos starten →